Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Juan C. Ramos, Joseph A. Sparano, Amy Chadburn, Erin G. Reid, Richard F. Ambinder, Eric R. Siegel, Page C. Moore, Paul G. Rubinstein, Christine M. Durand, Ethel Cesarman, David Aboulafia, Robert Baiocchi, Lee Ratner, Lawrence Kaplan, Adam A. Capoferri, Jeannette Y. Lee, Ronald Mitsuyasu, Ariela Noy

Blood (2020) 136 (11): 1284–1297.

https://doi.org/10.1182/blood.2019003959

Published: 2020

Includes: Supplemental data

Journal Articles

A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium

Lewis R. Silverman, MD, Amit Verma, MD, Rosalie Odchimar-Reissig, RN, Eric J. Feldman, MD, Shyamala C. Navada, MD, Erin P Demakos, RN, Maria R. Baer, MD, Vesna Najfeld, PhD, Joseph A Sparano, MD, Richard Piekarz, MD, PhD

Blood (2013) 122 (21): 386.

https://doi.org/10.1182/blood.V122.21.386.386

Published: 2013

Journal Articles

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

Blood (2013) 122 (19): 3251–3262.

https://doi.org/10.1182/blood-2013-04-498964

Published: 2013

Includes: Supplemental data

Journal Articles

ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era

Stefan K Barta, MD, MS, MRCP, Xiaonan Xue, Ph.D., Dan Wang, MS, Jeannette Y Lee, Ph.D., Lawrence D. Kaplan, MD, Josep-Maria Ribera, MD, PhD, Albert Oriol, Olga Garcia, Mireia Morgades, Michele Spina, MD, Umberto Tirelli, MD, Francois Boue, MD, PhD, Wyndham H. Wilson, MD, PhD, Christoph Wyen, MD, Kieron Dunleavy, MD, Joseph A Sparano, MD

Blood (2012) 120 (21): 1564.

https://doi.org/10.1182/blood.V120.21.1564.1564

Published: 2012

Journal Articles

A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes

Blood (2012) 120 (21): 3682.

https://doi.org/10.1182/blood.V120.21.3682.3682

Published: 2012

Journal Articles

Pooled Analysis of Aids-Malignancy Consortium (AMC) Trials Evaluating Rituximab Plus Either CHOP or Infusional EPOCH Chemotherapy In HIV-Associated Non-Hodgkin's Lymphoma

Stefan K Barta, MD, MRCP, Jeannette Y Lee, Ph.D., Joseph A Sparano, MD, Lawrence D Kaplan, MD, Ariela Noy, MD

Blood (2010) 116 (21): 1797.

https://doi.org/10.1182/blood.V116.21.1797.1797

Published: 2010

Journal Articles

Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (CDE) In Combination with HAART In HIV-Related Non-Hodgkin's Lymphomas (NHL)

Michele Spina, MD, Ulrich Jaeger, MD, Joseph A Sparano, Renato Talamini, Giuseppe Rossi, MD, Emanuela Vaccher, Umberto Tirelli

Blood (2010) 116 (21): 5072.

https://doi.org/10.1182/blood.V116.21.5072.5072

Published: 2010

Journal Articles

Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL

Adam M. Petrich, MD, Violetta V. Leshchenko, PhD, Pei-Yu Kuo, MS, B. Hilda Ye, PhD, Joseph A Sparano, MD, Samir Parekh, MD

Blood (2010) 116 (21): 436.

https://doi.org/10.1182/blood.V116.21.436.436

Published: 2010

Journal Articles

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

Blood (2010) 115 (15): 3008–3016.

https://doi.org/10.1182/blood-2009-08-231613

Published: 2010

Journal Articles

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010

Lawrence D. Kaplan, Jeannette Y. Lee, Richard F. Ambinder, Joseph A. Sparano, Ethel Cesarman, Amy Chadburn, Alexandra M. Levine, David T. Scadden

Blood (2005) 106 (5): 1538–1543.

https://doi.org/10.1182/blood-2005-04-1437

Published: 2005

Journal Articles

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials

Michele Spina, Ulrich Jaeger, Joseph A. Sparano, Renato Talamini, Cecilia Simonelli, Mariagrazia Michieli, Giuseppe Rossi, Ezio Nigra, Massimiliano Berretta, Chiara Cattaneo, Armin C. Rieger, Emanuela Vaccher, Umberto Tirelli

Blood (2005) 105 (5): 1891–1897.

https://doi.org/10.1182/blood-2004-08-3300

Published: 2005

Journal Articles

Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)

Joseph A. Sparano, Edie Weller, Tipu Nazeer, Thomas Habermann, Ann E. Traynor, Jane Manalo, Peter Cassileth

Blood (2002) 100 (5): 1634–1640.

https://doi.org/10.1182/blood.V100.5.1634.h81702001634_1634_1640

Published: 2002

NARROW

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

A Phase II Trial Of Epigenetic Modulators Vorinostat In Combination With Azacitidine (azaC) In Patients With The Myelodysplastic Syndrome (MDS): Initial Results Of Study 6898 Of The New York Cancer Consortium

Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients

ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era

A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes

Pooled Analysis of Aids-Malignancy Consortium (AMC) Trials Evaluating Rituximab Plus Either CHOP or Infusional EPOCH Chemotherapy In HIV-Associated Non-Hodgkin's Lymphoma

Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (CDE) In Combination with HAART In HIV-Related Non-Hodgkin's Lymphomas (NHL)

Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials

Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only